Mayne Pharma Revenue and Competitors

Mayne Pharma is an ASX listed specialty pharmaceutical Company (ASX: MYX) focused on applying its drug delivery expertise to commercialise branded and generic pharmaceuticals. Mayne Pharma also provides contract development and manufacturing services to more than 100 clients worldwide. Mayne Pharma's business units are: U.S. Generic Products - develops, markets and distributes generic products in the US, U.S. Specialty Brands - develops, markets and distributes specialty branded products in the US, Metrics Contract Services - provides contract pharmaceutical development, manufacturing and analytical services to third party customers globally, and Mayne Pharma International - develops, markets and distributes branded and generic products globally (ex-US). Here are some key facts about our company: 850+ staff US$1b market cap A$570m in revenue (July 2016 June 2017) A$35m invested in R&D (July 2016 June 2017) A product portfolio of 60+ molecules marketed in the US 30+ pipeline products in the US of which 14 products pending approval at the FDA The Company has grown substantially and reflects the hard work and dedication of our employees, whose work reflects these corporate values: Empowerment encouraging everyone to take initiative, enabling growth and achievement. Passion showing pride, enthusiasm and dedication in everything we do. Creativity delivering value and striving to connect new ideas with business realities. Agility operating with timeliness as well as mental, emotional and physical flexibility. Integrity maintaining high ethical standards, demonstrating honesty, and respecting fairness by doing the right thing, even when no one is looking. Accountability accepting our individual and team responsibilities, meeting our commitments, and acknowledging and learning from mistakes. To learn more, visit us at www.maynepharma.com

keywords:Biotechnology,Healthcare,Pharmaceuticals